alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 9,426–9,450 of 10,985 studies · free to read (page 378 of 440) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Risk Factors for Cognitive Impairment and Dementia Differ Across Classification Codes Evaluating Disadvantaged and Rural Regions in a Kentucky Appalachian Cohort

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-12-01

Diagnostic classifications, mean age, and education did not differ significantly across classifications. 5 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neighborhood Deprivation, Subjective and Objective Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2024-12-01

Neighborhood deprivation is associated with Future research should investigate the possible mechanisms of this association to identify optimal interventions at the neighborhood level. 5 key findings →

Participants: 596 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Geographic Variation in ADRD Prevalence and Mortality and Their Association with Social Vulnerability across US Counties: A Spatial Epidemiological Analysis Using NORC and CDC SVI Data

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Dementia and Geriatric Cognitive Disorders Extra 2026-04-02

Counties had a mean prevalence of 65.3 per 1,000 (SD 15.5) for highly likely ADRD and 123.5 per 1,000 (SD 27.0) for all determinations. 5 key findings →

Design: cross-sectional Participants: 3,108 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Mississippi Healthy Aging Data Report: Tools to Advance Health Equity

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Public Health in the Deep South 2024-08-09

The Mississippi Healthy Aging Data Report (see healthyagingdatareports.org) has helped policymakers, service providers, and advocates better understand the status of healthy aging in Mississippi. 5 key findings →

Participants: 663,581 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Social determinants of pharmacological dementia management: results from IDEAS

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-12-01

We used multilevel logistic regression with a random site intercept to test whether the probability of change in management associated with social determinants, race/ADI interactions with amyloid‐positivity, comorbidities, and clinical setting, adjusting for demographics. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer’s Disease and related dementias prevalence higher in Appalachian counties within Central Appalachia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2024-12-01

There is a consistent difference between Appalachian and non‐Appalachian counties, with Appalachian counties having relatively higher ADRD prevalence (in the range of 2.0‐3.0% times higher) than non‐Appalachian counties. 4 key findings →

Participants: 255 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Trends in Diagnosis of Dementia Subtypes in Nationwide Medicare Claims, 2015‐2021, by Race/Ethnicity, Sex, and Neighborhood Socioeconomic Status

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2024-12-01

In a national database of Medicare claims, there were substantial secular trends and differences in coding of dementia subtypes by race/ethnicity, sex, and neighborhood socioeconomic status. 2 key findings →

Participants: 100 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Comparison of plasma p‐tau217 and Aβ42/Aβ40 biomarkers by race to detect Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2024-12-01

P‐tau217/Aβ42 had the highest performance to discriminate Aβ+ from Aβ‐ (Table 1A,1B; all AUC≥0.90), and p‐tau217 showed excellent accuracy in ADNI sample (0.96; Table 1B). 2 key findings →

Participants: 213 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Exploring Neighborhood Level Socioeconomic Status and Volumetric MRI Results in Patients with Memory Impairment

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2024-12-01

Contrary to expectations, high versus low ADI groups only showed a difference in hippocampal volume, but in the reverse direction. 4 key findings →

Participants: 310 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

MCI Diagnosis and Neighborhood Disadvantage Predict Differences in White Matter Microstructure in a Rural Aging Cohort

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2024-12-01

These preliminary findings reveal white matter alterations associated with consensus MCI diagnosis and to socioeconomic differences in a clinical cohort of rural‐dwelling older adults. 5 key findings →

Participants: 69 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Associations between systemic inflammation, neighborhood tree canopy, and white matter hyperintensities: The Healthy Brain Initiative

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-12-01

Participants were 68.7±9.3 years old; 70% were female; 8% identified as Black, 89% White, as 3% other racial group; and 14% identified as Hispanic. 5 key findings →

Design: cross-sectional Participants: 161 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

“Who are you calling rural?”: An Analysis of Classification Codes Evaluating Disadvantage in Rural Regions and their Correlation in an Appalachian Kentucky Cohort

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-12-01

Proportions defined as living in a rural or disadvantaged area varied by classification, ranging from 13% to 27% of the cohort. 5 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

β-Amyloid PET Signal Reduction in Prior ARIA-E Regions after Antiamyloid Therapy for Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. American Journal of Neuroradiology 2025-11-19

In 4 of 5 patients treated with lecanemab or donanemab and who had moderate or severe ARIA-E, Aβ PET signal decreased significantly more in regions that had been involved with ARIA-E. Greater regional Aβ PET signal reduction in areas involved by ARIA-E may reflect enhanced local Aβ clearance, reduced tracer binding site availability, impaired glymphatic flow from immune complex deposition, or other mechanisms. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Association Between Polygenic Risk for Alzheimer's, Objective Sleep Architecture, and Plasma Neurofilament Light Chain in Midlife

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Health Wellness and Community Research 2026-01-15

PRS correlated positively with log-NFL (r = 0.31, p = 0.004) and inversely with N3 duration (r = −0.26, p = 0.017). 5 key findings →

Design: cross-sectional Participants: 84 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s Research & Therapy 2026-03-27

Participants’ motivations for testing and long-term adaptation to the results were strongly shaped by cognitive concerns and personal experiences of dementia in relatives. 5 key findings →

Participants: 17 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Hormone replacement therapy in women and vascular risk factors modify the association of a multi‐ancestry polygenic risk score with Alzheimer disease and related traits

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-12-01

The AD PRS was associated with AD in the ADSP sample, with odds ratios per standard deviation ranging from 1.14 to 1.52 across ancestry groups and robust validation in independent cohorts (Figure 1). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Novel early‐onset Alzheimer‐associated genes influence risk through dysregulation of glutamate, immune activation, and intracell signaling pathways

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-12-01

Alzheimer Disease (AD) is a highly polygenic dementia that presents with relatively earlier onset (≤65yo; EOAD) in about 5% of cases. 2 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed